Thanks for a great discussion so far! If anyone has a particular topic that he or she would like to address, please feel free to post a question directly or just send me a message!
For today and tomorrow, I'd like to continue our discussion on how this new data on CDX2 fits into our current and future approaches to adjuvant chemotherapy in stage II colon cancer.
As noted by Dr. Sargent and Dr. Dalerba yesterday, there are a variety of molecular features (such as MSI-H, TP53, BRAF, CIMP-H and now CDX2) that can be used to stratify tumors into subtypes. In addition, stage II disease, per the 2010 AJCC guidelines, is now subdivided into IIA, IIB, and IIIC based on tumor invasion (T3 vs. T4 primary). A variety of other clinicopathologic features (such as poor differentiation, bowel perforation or obstruction, lymphovascular or perineural invasion, inadequately sampled nodes, indeterminate or positive surgical margins, and high pre-operative CEA levels) have also been associated with "high risk" stage II disease. Furthermore, there are several adjuvant chemotherapy options, including oxaliplatin, 5-FU, and capecitabine, that have been studied in stage II and III disease.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.